Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes

The prevalence of both obesity and gestational diabetes mellitus (GDM) have increased, and each is associated with adverse perinatal outcomes including fetal overgrowth, neonatal morbidity, hypertensive disorders of pregnancy, and cesarean delivery. Women with GDM who are also overweight and obese have higher rates of pregnancy complications when compared to normal weight women with GDM, which may occur in part due to suboptimal glycemic control. The current recommendations for glycemic targets in pregnant women with diabetes are not rigorously defined, and they far exceed the mean fasting (70.9 ±7.8 mg/dL) and 1 hour post- prandial (108.9 ± 12.9 mg/dL) glucose values in pregnant women without GDM. Our prior work demonstrated that use of intensive (fasting \<90, 1 hr post-prandial \<120 mg/dL) compared to standard (fasting \<95 mg/dL, 1 hr post-prandial \<140 mg/dL) glycemic targets resulted in improved glycemic control without increasing the risk for hypoglycemia. The Intensive Glycemic Targets in Overweight and Obese Women with Gestational Diabetes Mellitus: A Multicenter Randomized Trial (iGDM Trial) is a large, pragmatic randomized clinical trial designed to investigate the impact of intensive versus standard glycemic targets on perinatal outcomes in women with GDM who are overweight and obese. During the 5-year project period, a multidisciplinary team of investigators from 4 medical centers representing regions of the U.S. with high rates of obesity will randomize 828 overweight and obese women with GDM to either intensive or standard glycemic targets. The specific aims of this project are: 1) Determine the effectiveness of intensive glycemic targets in reducing the risk for neonatal composite morbidity and large for gestational age birthweight in overweight and obese women with GDM, 2) Assess the safety of intensive glycemic targets as measured by the frequency of maternal hypoglycemia in overweight and obese women with GDM, and 3) Evaluate the cost-effectiveness of intensive glycemic control compared with standard glycemic control as measured by the incremental cost per case of neonatal morbidity and LGA birth weight prevented and per Quality-adjusted Life-year. The expected outcome of this study is high-quality evidence on the effectiveness, safety, and cost-effectiveness of intensive glycemic targets in reducing adverse perinatal outcomes among overweight and obese women with GDM. If proven effective, use of intensive glycemic targets in overweight and obese women with GDM will have an important positive impact on the health of these high risk women and their infants.

• Number of participants with large for gestational age birth weight [Срок оценки: Birth]
• Number of participants with neonatal hypoglycemia [Срок оценки: Within 24 hours of delivery]
• Number of participants with neonatal jaundice [Срок оценки: Within 7 days of delivery]
• Number of participants with respiratory distress syndrome [Срок оценки: Within 7 days of delivery]
• Maternal hyperglycemia [Срок оценки: From randomization to delivery]
• Early maternal glycemic levels [Срок оценки: 7 days after randomization]
• Pre-delivery maternal glycemic levels [Срок оценки: 14 days prior to delivery]
• Glycemic levels during study enrollment [Срок оценки: Up to 29 weeks]
• Episodes of maternal hypoglycemia [Срок оценки: From randomization to delivery]
• Number of episodes of symptomatic maternal hypoglycemia [Срок оценки: From randomization to delivery]
• Number of participants with hypertensive disorders of pregnancy (gestational hypertension and pre-eclampsia) [Срок оценки: From randomization up to 30 days after delivery]
• Number of participants with small for gestational age birth weight [Срок оценки: Birth]